ReviewFrontiers in medicine2026
Management of astigmatism in keratoconus with therapeutic refractive surgery.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astigmatism is a major determinant of visual impairment in keratoconus (KC), yet in this setting it cannot be understood as a simple cylindrical refractive error. Instead, it reflects a complex optical phenotype generated by anterior and posterior corneal asymmetry, epithelial remodeling, internal optical compensation, and progressive biomechanical instability, often in combination with coma-dominant higher-order aberrations. Beyond reducing monocular image quality, KC-related astigmatism may also compromise binocularity through interocular asymmetry, impaired binocular summation, reduced stereopsis, and visual discomfort. Management therefore depends not only on correcting refractive cylinder, but on distinguishing calculated astigmatic vectors from functionally relevant refractive astigmatism and identifying the relative contributions of irregular corneal optics, including coma, trefoil, and residual low-order error. Measurement remains challenging because corneal and manifest astigmatism frequently diverge, and because results are influenced by centration, analysis zone, device characteristics, and limited repeatability in more advanced disease. Current therapeutic refractive strategies are best viewed within an individualized, phenotype-driven framework rather than a mandatory linear sequence. Corneal collagen cross-linking remains fundamental when progression is present, but has limited refractive predictability. Corneal regularization procedures, including intracorneal ring segments, corneal allogeneic intrastromal ring segments, and customized surface ablation, may be selected when irregular corneal optics are the dominant cause of visual impairment. Once stability and sufficient regularity are achieved, toric phakic intraocular lenses, and in selected cases toric intraocular lenses, can address residual refractive error. Future progress will depend on multimodal imaging, improved phenotyping, and more individualized corneal shape-restoration strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.